We recently demonstrated that two members of the 19S regulatory complex, 26S proteasome non-ATPase subunits 1 (PSMD1) and 3 (PSMD3), may be potential targets for therapy in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia (CML) cells. Here, PSMD3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.